In their concluding remarks, Kinch et al suggest that the scaling back of internal R&D by large pharmaceutical companies, the rise of NME acquiring organizations with limited R&D capabilities and the tightening of venture capital funding for early stage biotechnology companies are resulting in a progressive and possibly irreversible shrinking of the R&D infrastructure for drug discovery. 1) Explain why you agree or disagree with this statement. 2) Where do you think the next generation of drugs will originate from?